Smithsolve

Smithsolve company information, Employees & Contact Information

Explore related pages

Related company profiles:

CONSIDER IT SOLVED It’s a bold statement given the complexity of communications in the biopharmaceutical industry. Every day, we fulfill this promise by solving business challenges for our clients, from advancing corporate reputation to explaining the science and economics of innovation. WE ARE SPECIALISTS We provide corporate communications and PR services to biopharmaceutical companies. We work exclusively in healthcare, applying our knowledge of science, medicine and the media. We gravitate toward companies with compelling missions and strong science. Clients involve us in diverse aspects of their business. OUR BUSINESS ACUMEN SETS US APART Collectively, we have worked at some of the world’s leading pharmaceutical and biotechnology companies, PR firms and patient organizations. Our senior-level team has the breadth of experience and depth of understanding to support your business. OUR VALUES ARE “OLD SCHOOL” We work hard and challenge ourselves to exceed expectations at every level. We are strategic in our thinking and disciplined in our execution. We pay attention to the details and produce clear and precise content. We make sure you have access to us whenever you need us. OUR APPROACH IS “NEW SCHOOL” We use a modern and integrated approach to accelerate your business success. Communications is a constantly evolving conversation with information flowing across audiences, geographies and media. The story belongs to the community, and your voice is one among many. Members from our team are certified in healthcare regulatory compliance for Public Relations, Digital Promotion, and Advertising/Promotion through the Center for Communication Compliance.
Looking for a particular Smithsolve employee's phone or email?

Smithsolve Questions

News

Dicerna Secures $70 Million in Convertible Preferred Stock Financing - Bain Capital

Dicerna Secures $70 Million in Convertible Preferred Stock Financing Bain Capital

Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies - Business Wire

Crossbow Therapeutics Nominates its Second Development Candidate, CBX-663, a Broadly Acting Therapeutic for a Wide Range of Solid and Hematologic Malignancies Business Wire

Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development - Business Wire

Valo Health and nference Announce Long-term Partnership to Accelerate Human-Centric Drug Discovery and Development Business Wire

Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD) - Business Wire

Aro Biotherapeutics Completes Enrollment in Phase 1b Trial of Targeted siRNA Therapy, ABX1100, in Late-Onset Pompe Disease (LOPD) Business Wire

Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies - Business Wire

Crossbow Therapeutics Doses First Patient in Phase 1 Trial of CBX-250 for Myeloid Malignancies Business Wire

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica - Business Wire

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica Business Wire

Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer - Business Wire

Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer Business Wire

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio - Business Wire

Melinta Therapeutics President and CEO Christine Ann Miller Elected to Board of Directors of Iveric Bio Business Wire

Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors - Business Wire

Iveric Bio Announces the Addition of Global Pharmaceutical Veteran, Christine Ann Miller, to its Board of Directors Business Wire

IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock - Business Wire

IVERIC bio, Inc. Announces Pricing of $100 Million Public Offering of Common Stock Business Wire

Top Smithsolve Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant